StreetInsider.com News Articles

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,600 at Macquarie

Thu, 28 May 2026 10:37:42 -0400

Macquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,600.00 (from JPY2,800.00) while maintaining a Outperform rating.

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,600 at Macquarie

Thu, 28 May 2026 10:37:42 -0400

Macquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,600.00 (from JPY2,800.00) while maintaining a Outperform rating.

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,600 at Macquarie

Thu, 28 May 2026 10:37:42 -0400

Macquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,600.00 (from JPY2,800.00) while maintaining a Outperform rating.

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,600 at Macquarie

Thu, 28 May 2026 10:37:42 -0400

Macquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,600.00 (from JPY2,800.00) while maintaining a Outperform rating.

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

Tue, 26 May 2026 02:45:00 -0400

- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s -

- CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate pipeline-led growth, allocate profit with discipline, and enhance enterprise productivity -

- Goals include initiating 10+ Phase 3 or pivotal studies by FY2030, delivering more than 4.3 trillion yen cumulative core OP before R&D, doubling revenue from Strategic Brands, and achieving minimum annual 2 yen dividend increase -

TOKYO, May 26, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced its

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

Tue, 26 May 2026 02:45:00 -0400

- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s -

- CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate pipeline-led growth, allocate profit with discipline, and enhance enterprise productivity -

TOKYO, May 26, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced its

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

Tue, 26 May 2026 02:45:00 -0400

- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s -

- CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate pipeline-led growth, allocate profit with discipline, and enhance enterprise productivity -

TOKYO, May 26, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced its

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

Tue, 26 May 2026 02:45:00 -0400

- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s -

- CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate pipeline-led growth, allocate profit with discipline, and enhance enterprise productivity -

TOKYO, May 26, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced its

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

Tue, 26 May 2026 02:45:00 -0400

- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s -

- CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate pipeline-led growth, allocate profit with discipline, and enhance enterprise productivity -

TOKYO, May 26, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced its

Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company

Tue, 26 May 2026 02:45:00 -0400

- Company sets ambition to achieve pipeline-led, record-high revenues by the mid-2030s -

- CSP2026 is a growth strategy that will deliver profitable growth and generate cash, accelerate pipeline-led growth, allocate profit with discipline, and enhance enterprise productivity -

TOKYO, May 26, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced its

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

Mon, 18 May 2026 08:00:00 -0400